Afficher la notice abrégée

dc.creatorSlart R.H.J.A., Glaudemans A.W.J.M., Gheysens O., Lubberink M., Kero T., Dweck M.R., Habib G., Gaemperli O., Saraste A., Gimelli A., Georgoulias P., Verberne H.J., Bucerius J., Rischpler C., Hyafil F., Erba P.A., 4Is Cardiovascular Imaging: a joint initiative of the European Association of Cardiovascular Imaging (EACVI), the European Association of Nuclear Medicine (EANM)en
dc.date.accessioned2023-01-31T09:58:05Z
dc.date.available2023-01-31T09:58:05Z
dc.date.issued2021
dc.identifier10.1007/s00259-020-05066-5
dc.identifier.issn16197070
dc.identifier.urihttp://hdl.handle.net/11615/79125
dc.description.abstractWith this document, we provide a standard for PET/(diagnostic) CT imaging procedures in cardiovascular diseases that are inflammatory, infective, infiltrative, or associated with dysfunctional innervation (4Is). This standard should be applied in clinical practice and integrated in clinical (multicenter) trials for optimal procedural standardization. A major focus is put on procedures using [18F]FDG, but 4Is PET radiopharmaceuticals beyond [18F]FDG are also described in this document. Whilst these novel tracers are currently mainly applied in early clinical trials, some multicenter trials are underway and we foresee in the near future their use in clinical care and inclusion in the clinical guidelines. Finally, PET/MR applications in 4Is cardiovascular diseases are also briefly described. Diagnosis and management of 4Is-related cardiovascular diseases are generally complex and often require a multidisciplinary approach by a team of experts. The new standards described herein should be applied when using PET/CT and PET/MR, within a multimodality imaging framework both in clinical practice and in clinical trials for 4Is cardiovascular indications. © 2020, The Author(s).en
dc.language.isoenen
dc.sourceEuropean Journal of Nuclear Medicine and Molecular Imagingen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85094146711&doi=10.1007%2fs00259-020-05066-5&partnerID=40&md5=faa7fa44ba759bf21929d1dfc89278ed
dc.subjectfluorodeoxyglucose f 18en
dc.subjectradiopharmaceutical agenten
dc.subjectArticleen
dc.subjectatherosclerosisen
dc.subjectblood vessel graften
dc.subjectcardiac imagingen
dc.subjectcardiac sarcoidosisen
dc.subjectcardiovascular diseaseen
dc.subjectclinical practiceen
dc.subjectcontrast enhancementen
dc.subjectdata analysisen
dc.subjectdevice infectionen
dc.subjectheart amyloidosisen
dc.subjectheart innervationen
dc.subjecthumanen
dc.subjectimage analysisen
dc.subjectimage reconstructionen
dc.subjectinfectionen
dc.subjectinflammationen
dc.subjectintersectoral collaborationen
dc.subjectlarge vessel vasculitisen
dc.subjectmulticenter study (topic)en
dc.subjectmultidisciplinary teamen
dc.subjectnuclear magnetic resonance imagingen
dc.subjectpositron emission tomographyen
dc.subjectpositron emission tomography-computed tomographyen
dc.subjectpractice guidelineen
dc.subjectprosthetic valve endocarditisen
dc.subjectquantitative analysisen
dc.subjectstandardizationen
dc.subjectclinical trialen
dc.subjectdiagnostic imagingen
dc.subjectmulticenter studyen
dc.subjectstandarden
dc.subjectx-ray computed tomographyen
dc.subjectCardiovascular Diseasesen
dc.subjectFluorodeoxyglucose F18en
dc.subjectHumansen
dc.subjectPositron Emission Tomography Computed Tomographyen
dc.subjectPositron-Emission Tomographyen
dc.subjectRadiopharmaceuticalsen
dc.subjectReference Standardsen
dc.subjectTomography, X-Ray Computeden
dc.subjectSpringer Science and Business Media Deutschland GmbHen
dc.titleProcedural recommendations of cardiac PET/CT imaging: standardization in inflammatory-, infective-, infiltrative-, and innervation (4Is)-related cardiovascular diseases: a joint collaboration of the EACVI and the EANMen
dc.typejournalArticleen


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée